Preliminary Administration of EPO and Markers of Cardiac Ischemia Induced by CPB

• Status: Completed
• Trial end date: 2009-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The main objective is to observe the effects of erythropoietin administration on different blood markers of ischaemic cardiac lesions induced by cardiopulmonary bypass.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Grenoble
• Collaborator: Roche Pharma AG
• Treatments: Epoetin Alfa

Criteria

Inclusion Criteria:

• Coronary bypass surgery.

• Surgery not urgent.

• Left ventricular ejection fraction (LVEF) > 40.

• Informed consent form signed.

Exclusion Criteria:

• Valvular surgery.

• Surgery with beating heart, with or without cardiopulmonary bypass.

• Carotid bypass surgery.

• Myocardial infarction less than 30 days.

• Previous history of cardiac surgery.

• Kidney failure (creatinine > 200 µmol/l).

• Uncontrolled hypertension.

• Unstable angina.

• Risk of deep venous thrombosis.

• Vascular cerebral attack less than 30 days.

• Malignant tumour.

• Phenylketonuria.

• Allergy to erythropoietin.

• Previous programmed blood donation.

• Pregnancy and feeding.